The GetReal consortium ("incorporating real-life data into drug development") addresses the efficacy-18 19 effectiveness gap that opens between the data from well-controlled randomized trials in selected patient 19 20 groups submitted to regulators and the real-world evidence on effectiveness and safety of drugs required 20 21
by decision makers. Workpackage 4 of GetReal develops evidence synthesis and modelling approaches to 21 22
generate the real-world evidence. In this commentary, we discuss how questions change when moving 22 23 from the well-controlled randomized trial setting to real-life medical practice, the evidence required to 23 answer these questions, the populations to which estimates will be applicable to and the methods and 24 data sources used to produce these estimates. We then introduce the methodological reviews written by 24
25
GetReal authors and published in Research Synthesis Methods on network meta-analysis (Efthimiou et al., 25 26 2016) , individual patient data meta-analysis (Debray et al., 2015) and mathematical modelling to predict Q3 26 27 drug effectiveness (Panayidou et al., 2016) . The critical reviews of key methods are a good starting point 27 28
for the ambitious programme of work GetReal has embarked on. The randomized clinical trial is the most reliable study design to determine the efficacy and safety of drugs.
35
However, the clinical trials system has been described as "broken," "in crisis" and "not fit for purpose": many trials 35 36
do not achieve patient enrolment targets; spiralling costs and complex regulatory and monitoring requirements 36 37 prevent the conduct of others; and many completed trials do not answer clinically relevant questions or are not 37 38 applicable to everyday medical practice but are driven by commercial considerations (DeVita, 2008; Vickers, 38 39 2014; Loudon et al., 2013 30  31  31  32  32  33  33  34  34  35  35  36  36  37  37  38  38  39  39  40  40  41  41  42  42  43  43  44  44  45  45  46  46  47  47  48  48  49  49  50  50  51  51  52  52  53  53  54  54  55  55  56  56  57  57  58  58  59  59  60  60  61  61  62  62  63  63  64 64 65 we use network meta-analysis approaches of aggregate study results to obtain estimates of relative efficacy from 2 3 several randomized trials. One of the drugs in the network is, for the sake of the argument, designated as the "new 3 4 kid on the block," and the trials of this drug are assumed to be prelaunch, whereas the other drugs are assumed to 4 5 be on the market. Subsequently, individual participant data (IPD) provided by the participating pharmaceutical 5 6 companies and observational data from clinical databases and disease registries are combined to identify 6 7 important factors that modify the drug's relative effectiveness and to estimate its performance in patient 7 8 populations that will likely receive the drug after launch. Of note, at this stage, the relative effectiveness of the 8 9 drug continues to be estimated under randomized study conditions, rather than real-world conditions (Table 1) . 9 10
For example, adherence to treatments is implicitly assumed to correspond to that observed in the phase II/III trials.
11
The next step is to account for the messy real world, where doctors decide who will receive the new drug, 11 12
influenced by guidelines, patient characteristics and preferences, and other factors. In order to gauge relative 12 13 effectiveness, these decisions need to be understood as well as the possible confounding factors that may be 13 14 associated with the probability both of receiving the drug and of developing the outcome and the variables that 14 15 may be associated with the treatment (but not with the outcomes) or of variables associated with outcomes (but 15 16 not treatment). The likely adherence to the new drug and to the comparator drugs is also relevant. summarize the key issues involved, including novel methods for measuring and detecting inconsistency in the 25 26 network, dealing with effect modification, ways for adjusting for possible sources of bias and the reporting of 26 27 the results of a network meta-analysis (Efthimiou et al., 2016) . IPD meta-analysis is widely considered to be the 27 28 gold standard in meta-analytic research, but in their review, Debray et al. stress that they are no panacea to the 28 29 limitations of the included studies. Also, IPD meta-analyses are major undertakings, which cannot be performed 29 30
ad hoc or on a shoe string, and their potential advantages, for example, the powerful investigation of interaction 30 31
and subgroup effects, must be carefully weighed against the extra efforts involved (Debray et al., 2015) . Finally, 31 32
Panayidou and colleagues comprehensively searched for studies that predicted real-world effectiveness from 32 33 randomized controlled trial data. Of note, they found only 12 articles and four modelling approaches, mainly 33 34
Markov multistate models (Panayidou et al., 2016) . Although most studies included sensitivity analyses, external 34 35 validation was rarely performed.
36
The critical reviews of the key methodologies published in the Research Synthesis Methods are a good starting 36 37 point for the ambitious programme of work the GetReal consortium has embarked on. 19  20  20  21  21  22  22  23  23  24  24  25  25  26  26  27  27  28  28  29  29  30  30  31  31  32  32  33  33  34  34  35  35  36  36  37  37  38  38  39  39  40  40  41  41  42  42  43  43  44  44  45  45  46  46  47  47  48  48  49  49  50  50  51  51  52  52  53  53  54  54  55  55  56  56  57  57  58  58  59  59  60  60  61  61  62  62  63  63  64 64 65
Author Query Form Journal: Research Synthesis Methods
Article: jrsm_1207
Dear Author, During the copyediting of your paper, the following queries arose. Please respond to these by annotating your proofs with the necessary changes/additions.
• If you intend to annotate your proof electronically, please refer to the E-annotation guidelines.
• If you intend to annotate your proof by means of hard-copy mark-up, please use the standard proofing marks. If manually writing corrections on your proof and returning it by fax, do not write too close to the edge of the paper. Please remember that illegible mark-ups may delay publication. Whether you opt for hard-copy or electronic annotation of your proofs, we recommend that you provide additional clarification of answers to queries by entering your answers on the query sheet, in addition to the text mark-up. 
